Skip to main content

Table 3 Multivariate Cox proportional hazards ratios and 95% confidence intervals for the association between EndoPredict, selected clinicopathological variables and metastasis-free survival

From: Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial

Variables

HR (95% CIa)

P-value

EP

1.126 (1.041 to 1.219)

0.0031

Number Positive Nodes

 

<0.0001b

  1 to 3

Reference value

 

  4 to 10

1.420 (0.932 to 2.166)

0.1030

  >10

3.605 (2.102 to 6.185)

<0.0001

Age

0.983 (0.966 to 1.001)

0.0628

Tumor size

 

0.6631b

  ≤1 cm

Reference value

 

  >1 to ≤2 cm

0.789 (0.343 to 1.816)

0.5774

  >2 to ≤5 cm

1.042 (0.466 to 2.331)

0.9196

  >5 cm

0.880 (0.301 to 2.577)

0.8159

Treatment arm

 

0.9331b

  FEC

Reference value

 

  FEC-P

1.016 (0.697 to 1.482)

 

Grade

 

0.4650b

  G1

Reference value

 

  G2

1.662 (0.830 to 3.329)

0.1519

  G3

1.589 (0.747 to 3.377)

0.2290

  Unknown

1.198 (0.470 to 3.052)

0.7051

ER (Allred score c )

0.980 (0.903 to 1.063)

0.6207

PR (Allred score c )

0.965 (0.902 to 1.032)

0.2947

Ki67 quantitative

1.001 (0.986 to 1.016)

0.8982

  1. aCI: Confidence interval; EP: EndoPredict; EPclin: Combined molecular and clinical score; ER: Estrogen receptor; HR: Hazard ratio; MFS: Metastasis-free survival; PR: Progesterone receptor. bP-value of the variable’s overall effect on MFS. cAllred et al. [18]. Multivariate analyses included 534 patients and 116 events.